Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective study DOI
Fumihiko Urabe,

Y Taneda,

Naoki Uchida

et al.

Japanese Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: April 8, 2025

Abstract Background Despite advancements in treatment options for metastatic urothelial carcinoma (mUC), therapeutic choices remain limited patients with disease refractory to platinum-based chemotherapy (PBC) and immune checkpoint inhibitors (ICIs). Enfortumab vedotin (EV) has demonstrated significant efficacy later lines of therapy mUC; however, its organ-specific responses uncertain. Methods We conducted a retrospective study 69 mUC who received EV following PBC ICIs. Efficacy was assessed using Response Evaluation Criteria Solid Tumors, response rates (OSRR) control (OSCR) calculated across different sites. Multivariate Cox regression analysis performed identify independent predictors progression survival. Results The median progression-free survival (PFS) 8.3 months, whereas the overall (OS) 18.0 months. objective rate (ORR) 53.6%, (DCR) 82.6%. OSCR ≥70% all sites, confirming broad EV. Liver metastases exhibited highest OSRR at 66.7%, bone had lowest 12.5%. Tumor burden reduction significantly lower compared other Disease predominantly observed target lesions, time 3 Eastern Cooperative Oncology Group performance status serum C-reactive protein levels were identified as PFS OS. Conclusion favorable tumor mUC, particularly high against liver metastasis. However, metastases. No differences observed.

Language: Английский

Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective study DOI
Fumihiko Urabe,

Y Taneda,

Naoki Uchida

et al.

Japanese Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: April 8, 2025

Abstract Background Despite advancements in treatment options for metastatic urothelial carcinoma (mUC), therapeutic choices remain limited patients with disease refractory to platinum-based chemotherapy (PBC) and immune checkpoint inhibitors (ICIs). Enfortumab vedotin (EV) has demonstrated significant efficacy later lines of therapy mUC; however, its organ-specific responses uncertain. Methods We conducted a retrospective study 69 mUC who received EV following PBC ICIs. Efficacy was assessed using Response Evaluation Criteria Solid Tumors, response rates (OSRR) control (OSCR) calculated across different sites. Multivariate Cox regression analysis performed identify independent predictors progression survival. Results The median progression-free survival (PFS) 8.3 months, whereas the overall (OS) 18.0 months. objective rate (ORR) 53.6%, (DCR) 82.6%. OSCR ≥70% all sites, confirming broad EV. Liver metastases exhibited highest OSRR at 66.7%, bone had lowest 12.5%. Tumor burden reduction significantly lower compared other Disease predominantly observed target lesions, time 3 Eastern Cooperative Oncology Group performance status serum C-reactive protein levels were identified as PFS OS. Conclusion favorable tumor mUC, particularly high against liver metastasis. However, metastases. No differences observed.

Language: Английский

Citations

0